Compare Organon & Co. Common Stock (OGN) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Prospect Capital Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Prospect Capital Corporation trades at $1.58 (market cap $891.47M). The key difference: Organon & Co. Common Stock is far larger — about 4.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (25.15%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Prospect Capital Corporation for 78 Days on average.
| OGN | PSEC | |
|---|---|---|
Market Cap | $3.62B | $891.47M |
Volume | 2,892,999 | 4,809,352 |
Sector | Health | Financials |
52-Week High | $13.81 | $3.05 |
52-Week Low | $5.70 | $1.60 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $11.04B | $2.65B |
Dividend Yield | 0.58% | 25.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PSEC trades at $1.60, down 7.51% with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly earnings have consistently beaten expectations, though the company maintains a modest 25% analyst buy rating amid ongoing dividend distributions of $0.04 monthly.
Outlook remains cautious due to negative cash flow and volatile revenue patterns. The 18%+ dividend yield attracts income investors but carries sustainability risks given declining NAV and portfolio contraction. Analyst consensus leans neutral with 55% hold ratings, reflecting concerns about long-term performance stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
